Survival outcomes of management in metastatic gastric adenocarcinoma patients

Huang Ming Hu; Hui Jen Tsai; Hsiu Ying Ku; Su Shun Lo; Yan Shen Shan; Hung Chi Chang; Yee Chao; Jen Shi Chen; Shu Chen Chen; Chun Ju Chiang; Anna Fen Yau Li; Hsiu Po Wang; Tsang En Wang; Li Yuan Bai; Ming Shiang Wu; Li Tzong Chen; Tsang Wu Liu; Yi Hsin Yang

doi:10.1038/s41598-021-02391-z

Survival outcomes of management in metastatic gastric adenocarcinoma patients

Huang Ming Hu, Hui Jen Tsai, Hsiu Ying Ku, Su Shun Lo, Yan Shen Shan, Hung Chi Chang, Yee Chao, Jen Shi Chen, Shu Chen Chen, Chun Ju Chiang, Anna Fen Yau Li, Hsiu Po Wang, Tsang En Wang, Li Yuan Bai, Ming Shiang Wu, Li Tzong Chen, Tsang Wu Liu^*, Yi Hsin Yang^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.

Original language	English
Article number	23142
Journal	Scientific reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-02391-z
State	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-021-02391-z

Cite this

Hu, H. M., Tsai, H. J., Ku, H. Y., Lo, S. S., Shan, Y. S., Chang, H. C., Chao, Y., Chen, J. S., Chen, S. C., Chiang, C. J., Li, A. F. Y., Wang, H. P., Wang, T. E., Bai, L. Y., Wu, M. S., Chen, L. T., Liu, T. W., & Yang, Y. H. (2021). Survival outcomes of management in metastatic gastric adenocarcinoma patients. Scientific reports, 11(1), Article 23142. https://doi.org/10.1038/s41598-021-02391-z

@article{1663222ce3b14ae79692534a85c96cfd,

title = "Survival outcomes of management in metastatic gastric adenocarcinoma patients",

abstract = "Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.",

author = "Hu, {Huang Ming} and Tsai, {Hui Jen} and Ku, {Hsiu Ying} and Lo, {Su Shun} and Shan, {Yan Shen} and Chang, {Hung Chi} and Yee Chao and Chen, {Jen Shi} and Chen, {Shu Chen} and Chiang, {Chun Ju} and Li, {Anna Fen Yau} and Wang, {Hsiu Po} and Wang, {Tsang En} and Bai, {Li Yuan} and Wu, {Ming Shiang} and Chen, {Li Tzong} and Liu, {Tsang Wu} and Yang, {Yi Hsin}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-02391-z",

language = "English",

volume = "11",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Survival outcomes of management in metastatic gastric adenocarcinoma patients

AU - Hu, Huang Ming

AU - Tsai, Hui Jen

AU - Ku, Hsiu Ying

AU - Lo, Su Shun

AU - Shan, Yan Shen

AU - Chang, Hung Chi

AU - Chao, Yee

AU - Chen, Jen Shi

AU - Chen, Shu Chen

AU - Chiang, Chun Ju

AU - Li, Anna Fen Yau

AU - Wang, Hsiu Po

AU - Wang, Tsang En

AU - Bai, Li Yuan

AU - Wu, Ming Shiang

AU - Chen, Li Tzong

AU - Liu, Tsang Wu

AU - Yang, Yi Hsin

PY - 2021/12

Y1 - 2021/12

N2 - Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.

AB - Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85120177324&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-02391-z

DO - 10.1038/s41598-021-02391-z

M3 - Article

C2 - 34848751

AN - SCOPUS:85120177324

SN - 2045-2322

VL - 11

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 23142

ER -

Survival outcomes of management in metastatic gastric adenocarcinoma patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this